Patent ID: 7964604

Claim:
A pharmaceutical composition comprising an effective amount of bifeprunox, a crystalline polymorph of 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate, and at least one pharmaceutically acceptable excipient, wherein the effective amount of bifeprunox comprises a maintenance treatment dose and following administration of the composition to a human subject, the subject exhibits at least one of: (a) a plasma T max from about 0.5 to about 8.0 hours; (b) a plasma C max of at least about 62.1±38.2 ng/ml; or (c) a plasma AUC 0-24 of at least about 401.5±292.2 hr·ng/ml.